Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of tamibarotene plus azacitidine in newly diagnosed RARA-positive higher-risk myelodysplastic syndrome
MOH_2022-06-12_010742Phase 3Recruiting
- Sponsor
- Syros Pharmaceuticals
- Start
- Jun 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myelodysplastic syndrome (MDS) comparing tamibarotene plus azacitidine with placebo plus azacitidine (2 arms). Started Jun 2022; status: recruiting.
02
Drugs
tamibarotene
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on MOH_2022-06-12_010742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-06-12_010742.